Get started

Healthcare

🤔 Healthcare Potential Booming Company?I have a long list as to why this is good. To just dumb it down, it's getting ready to potentially reverse. Check Kagi, Heikin, Baseline (I don't like the "stick" charts), and the regular candle to see where the original retest point was of the shoulder engulfing seller candle. Price has retested that point across all charts and is showing a complete slow down. Price sat at around 5.96 and below for quite some time due to the support level and is showing signs of major slowdown on the Heikin chart. Try baseline for a clearer version of the slowdown but aside from that, don't use it unless you're double checking your work. Anyways, I'm in. Enjoy if you do, if not thanks for reading. Note* I did not proof read, sending as is.
VLong
by Cordali
3
healthcare is outperforming the broader market (XLV)when an overweight sector corrects with the market volatility is higher in general, but thats why it bounces so much more quickly and outperforms other sectors in the same trend. sector rotation will have a play in healthcare if we find a higher low, and bulls have given themselves room to complete that reversal. we should make a higher low somewhere, even if its closer to the bottom than i anticipate, and continue to rally faster than other parts of the market as stocks benefitting from inflow seeking value accumulates.
AMEX:XLVLong
by cerealtrades
Healthcare is still in a bull market - be longAt the start of 2022, healthcare stocks have gotten killed, especially anything that was a winner in the past 1-2 years. A lot of people are getting rather bearish, but they shouldn't be. The fundamentals favor healthcare still in many ways, and momentum is still rather strong. We already got the breakout in healthcare stocks, and we just got the retest, which was enough to scare a lot of people out. Now is a great entry for a long position, coming out of a short consolidation into a potential new bull phase.
AMEX:XLVLong
by GTStockmaster
$ARKG - Weekly TF AnalysisThe macro count is pretty clear. We're below the 38.2% fib of the impulsive move from the covid lows, and approaching the 50% fib as well as the bottom of the channel. The weekly RSI is lower then even the covid lows of march 2020. In fact the RSI hasn't been this low since inception in 2016. As with all of ARK's ETF's these are long term plays. If you want biotech exposure, this is a great time to buy this ETF. Ask yourself, do you think the healthcare industry is likely to be more profitable over the next 5 years or less profitable? Do you think innovations in gene editing, DNA sequencing and mRNA technology is going to increase or have we peaked in this era of perpetual covid?
CBOE:ARKGLong
by ir-rizzle
Pfizer (PFE) to continue its BULL run in 2022!Fundamental Analysis Pfizer, Inc. has consistently been one of the largest pharmaceutical companies in the world for the better part of the last two decades. The company has a remarkable history going back all the way to the year 1849, when Pfizer was founded in Brooklyn, New York. The large cap pharma giant has developed a well-balanced and deep portfolio of products in key areas like Inflammation and Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines etc. However, it seems that as a result of the success of Pfizer's vaccine COVID-19 treatments, many investors have forgotten about the rest of Pfizer's business and how successful it continues to be. It is true that the sales of its COVID-19 vaccine ($36 billion in 2021 alone) have managed to nearly double Pfizer's annual revenue from $41.9 billion in 2020 to over $78 billion in 2021. What's even more important is that the strong sales growth has also translated into higher profits for the company as its profit margins before interest and taxes, referred to as EBIT margin, have risen over the past year. This shows that Pfizer has managed its R&D and all other fixed and operating costs associated with development, production and distribution efficiently, thus improving the profitability ratios of the company. The large cap pharma giant has also managed to almost triple the size of its free cash flow to more than $29 billion over the past twelve months compared to only $11.6 billion in 2020. More free cash flow makes a business more robust, giving Pfizer more money to invest in research and development of new products, pay more in dividends, or strengthen its balance sheet. The company currently has a total of 94 drugs in the pipeline spread across critical treatment areas like Inflammation and Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines etc. all waiting regulatory approval. - Phase 1(27); Phase 2 (29); Phase 3 (29); Registration (9) Looking at the outstanding track record of Pfizer's drug development capabilities, we can easily state that the company will continue to be a leader in the sector that it operates in. Macro view The equity markets in the US are currently undergoing a process of meaningful repricing and re-valuation of what companies are actually worth, as everyone is getting ready for the Federal Reserve to start raising interest rates in the US and tighten its monetary policy. In a rising interest rate environment, investors tend to move away from expensive high-growth stocks trading at unreasonably high P/E and P/S valuations as the tighter monetary policy environment makes it much more difficult and more expensive for such companies to borrow and invest capital and produce the high earnings growth that investors expect from them. Well-established large cap Healthcare and Biotech stocks are considered to be least correlated with the monetary policy situation in the country as they tend to trade more on FDA drug approvals and drug-related announcements rather than actual earnings per share. Most of the leaders in this space also have a substantial pricing power, as people using their medicines are doing so because they need them and because the drugs are helping them get better. Thus, owning Healthcare and Biotech stocks in a rising inflation and interest rate environment is a defensive play that could end up paying off big time, as stocks in these sectors are rather volatile. Technical Analysis The stock has experienced a volatile retracement from its $61 all-time highs and is currently in a corrective phase. However, the uptrend is still intact as the price is well above both the strong horizontal support at $51 and the upward sloping diagonal support (blue line) at $44. Furthermore, the stock is trading above its 5, 20, 50, 200 EMAs, which is also a bullish continuation signal. We expect buyers to start coming in around the $52-53 level, thus establishing the next higher high. Once that is done, the stock will re-test its ATH at around $61 in Q1 of this year. The broad market framework, together with the many positive company related developments in the coming months are expected to bring enough momentum to the stock in order for it to break its previous ATH and set a new one sometime in Q2. Our target for the stock in H1 of 2022 is around the $68 level, which is roughly 30% higher from the current levels. Follow and Copy us on eToro for more detailed market analyses, profitable trading ideas and a consistent portfolio performance. [ b] Sincerely, @DowExperts
NYSE:PFELong
by DowExperts
How I almost doubled my investments by betting in AIBig wins for 2020 and 2021! Exactly today two years ago I posted this idea about investing in FANG (Facebook, Amazon, Nvidia and Google). If you followed my advice and invested in FANG you should have almost doubled your investment by now. Remember that the idea behind picking these stock is very simple: These companies have a lot of data, and data is the oil for AI . My investing advice remains the same for the 2022. Avoid investing in meme stocks and unknown crypto coins. This is a very hard way to make any money. Invest in companies related to what is coming next. Invest in AI, ML, healthcare, robotics, 3d printing, drones, biotech. Worth reading: USDOF Official Calls Artificial Intelligence the New Oil . Follow me on TradingView to know more about my investing choices. --- “Robots are not going to replace humans, they are going to make their jobs much more humane. Difficult, demeaning, demanding, dangerous, dull – these are the jobs robots will be taking." - Sabine Hauert, Co-founder of Robohub.org
NASDAQ:META
by adelriosantiago
Cofinimmo (COFB.br) bearish scenario:The technical figure Triangle can be found in the Belgian company Cofinimmo SA(COFB.br) at daily chart. Cofinimmo is the foremost listed Belgian real estate company specialising in rental property. The company owns a property portfolio worth over €4 billion, representing a total area of nearly 2,000,000m² spread over Belgium, The Netherlands, France, Germany and Spain. Its main investment segments are healthcare properties (nursing and care homes, revalidation clinics, psychiatric clinics, medical office buildings,...) and offices, and property of distribution networks (portfolio of pubs let to AB InBev and portfolio of insurance branches let to MAAF). The Triangle has broken through the support line on 21/12/2021, if the price holds below this level you can have a possible bearish price movement with a forecast for the next 17 days towards 131.30 EUR. Your stop loss order according to experts should be placed at 140.40 EUR if you decide to enter this position. Belgium-based real estate investor, Cofinimmo, has announced another round of acquisitions. It will acquire three nursing and care homes in Germany – two in Essenheim and one in Bruchmühlbach-Miesau, and plans to build a new property in Andalucia, Spain. The investment for the three sites in Germany amounts to approximately €39m. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
EURONEXT:COFBShort
by legacyFXofficial
JD.com's Healthcare Unit Prepare for Next Battle Affected heavily by recent technological advancements, the sector may soon attract Chinese regulators' attention. Background 2021 turned out to become a positive year for China's healthcare industry, where the gigantic demand stems from the aging population, growing individual wealth, and – more importantly – the COVID-19 crisis' aftermath. The market has grown consistently; in 2020, the growth rate slumped to 7.2% due to the massive lockdowns, although it is expected to rise back to 17.6% in 2021 with a total market size of CNY 8.7 trillion. Despite this, the market remains relatively undeveloped – since 2016, the Chinese authorities have been working on creating a CNY 16 trillion healthcare ecosystem by 2030. Online healthcare is in the limelight The pandemic challenged people's sense of well-being and facilitated their desire and determination to become more active and engaged in managing their health, which also boosted the need for remote medical consultations and online medicine sales. According to Deloitte, the portion of consumers who have used virtual visits rose from 15% to 19% from 2019 to early 2020, then jumped to 28% in April 2020. In fact, consumers plan to continue using the – 80% of the Deloitte survey respondents are likely to keep using other online services even post COVID-19. Jessica Tan, co-CEO of Ping An Group, once said that around 20% to 25% of healthcare services in China could be moved to the online space. This will present new opportunities to the most competitive businesses in this field. Among these, JD Health (6618:HK) and Alibaba Health (0241:HK) are two tech giant-backed companies that have ridden this surging wave quite well. The latecomer, JD Health, is moving really fast – only four months' independent operation since May 2019 before it filed a public offering. In August 2020, JD Health ranked 35th on Hurun Global Unicorn Index 2020 with a valuation at CNY 50 billion, which crowned it as the world's youngest unicorn. Different from traditional platforms, JD Health has established various online and offline integrated businesses, including JD Pharmacy, JD Health Internet Hospital and Pharmacy Alliance. How does JD.com compare in healthcare endeavors? Financial performance In September 2021, JD Health released its interim financial report with relatively strong results. Its total revenue increased by over half (55.4%), from CNY 8.8 billion in H1 2020 to CNY 13.6 billion in H1 2021, which was primarily due to the increase in revenue from sales of pharmaceutical and healthcare products within the reporting period. In fact, this continuous upward trend also shows in its gross profit for the past four fiscal years, although the loss enlarged even further in 2020 when compared with the previous years. Another catalyst for the growth could be the increase in JD Health's number of Annual Active User (AAU) accounts. As of June 30, 2021, the AAUs in the past 12 months reached 109 million, representing a net addition of over 18.8 million as compared with that of 2020. The growing number also shows that the stickiness of users has been well improved as well as its brand awareness. In other words, JD Health's constant investment in marketing activities – its selling and marketing expenses almost doubled for two consecutive fiscal years – finally began to work. JD's supply chain infrastructure casts its core barrier Although JD Health is relatively inferior to its competitor in terms of annual active users – 109 million as of June 30, 2021 – JD Health's revenue is all the way higher than that of its closest competitor, Alibaba Health, more specifically, the revenue as nearly two times higher. One booster is its complete business structure. Integrating B2B/B2C/O2O businesses, JD Health can have more wings – for example, along with the retail pharmacy, JD Health also offers its own family doctor services, online hospital services as well as smart healthcare solutions. Through the integration of pharmaceutical retail businesses and online healthcare services, the medical products users also become target customers for other consumption healthcare units, and vice versa; a closed cycle hence is developed and can also be seen in its ever-growing operating income at a CAGR of 11%. JD Logistics is another catalyst supporting the healthcare unit's strong performance, being one of the leading supply chain players in the field of medicine now. Through JD Logistics, JD Health is able to connect with upstream, midstream and downstream enterprises: from industrial enterprises and healthcare institutions to offline pharmacies and dental clinics. This absolute advantage over comparable companies enables JD Health to further cut its fulfillment costs to around 10% of total revenue, which is related to warehousing, logistics and customer service expenditures incurred by the self-operated pharmaceutical business. Future in the mist The future won't be easy for both Alibaba Health and JD Health, as the competition is intensifying. Except for the 'peer pressure,' some inherent problems exist in the essence of most healthcare services – those are mainly related to professionalism, trust and quality. It is partly because of the particularity of healthcare services and pharmaceutical drugs along with the recent market chaos, the government has tightened supervision increasingly, more than ever before. Rory Green, a China economist at TS Lombard, said that the healthcare sector is the only one not hit by regulatory scrutiny yet but is particularly vulnerable, which may possibly make it the next target. For the full article with the charts, please visit the original link.
HKEX:6618
by EqualOcean
Alibaba Healthcare Units Prepares for Next Battle in HealthcareAffected heavily by recent technological advancements, the sector may soon attract Chinese regulators' attention. Background 2021 turned out to become a positive year for China's healthcare industry, where the gigantic demand stems from the aging population, growing individual wealth, and – more importantly – the COVID-19 crisis' aftermath. The market has grown consistently; in 2020, the growth rate slumped to 7.2% due to the massive lockdowns, although it is expected to rise back to 17.6% in 2021 with a total market size of CNY 8.7 trillion. Despite this, the market remains relatively undeveloped – since 2016, the Chinese authorities have been working on creating a CNY 16 trillion healthcare ecosystem by 2030. Online healthcare is in the limelight The pandemic challenged people's sense of well-being and facilitated their desire and determination to become more active and engaged in managing their health, which also boosted the need for remote medical consultations and online medicine sales. According to Deloitte, the portion of consumers who have used virtual visits rose from 15% to 19% from 2019 to early 2020, then jumped to 28% in April 2020. In fact, consumers plan to continue using the – 80% of the Deloitte survey respondents are likely to keep using other online services even post COVID-19. Jessica Tan, co-CEO of Ping An Group, once said that around 20% to 25% of healthcare services in China could be moved to the online space. This will present new opportunities to the most competitive businesses in this field. Among these, JD Health (6618:HK) and Alibaba Health (0241:HK) are two tech giant-backed companies that have ridden this surging wave quite well. Alibaba (BABA:NASDAQ) is deemed to be the first explorer among Chinese tech giants, having joined the game as early as 1998 by founding Alibaba Health (0241:HK). In fact, it is the first Chinese Internet-healthcare company to go public on the Hong Kong Stock Exchange. Alibaba Health is primarily engaged in the pharmaceutical direct sales business, the pharmaceutical e-commerce platform business, medical and healthcare services platforms and digital infrastructure business and related services, though it wants to take off the 'e-pharmacy' tag for long. How does Alibaba compare in the healthcare endeavors? Financial Performance Alibaba Health finally became fully profitable in its fiscal 2021, when the revenue reached CNY 15.52 billion Among four major businesses, medicine remains the main contributor to its revenue, amounting to CNY 13.21 billion, or about 85% of the total revenue. The rest is contributed by pharmaceutical e-commerce platform business, the medical health service business and digital infrastructure business, with revenues of CNY 1.96 billion, CNY 284 million and CNY 53 million respectively. Benefiting from the improving cost control ability and the emerging economies of scale, the overall expenses of Alibaba Health are far less than that of JD Health for every comparable fiscal year. BABA's backing is the ace card of Alibaba Health As the healthcare business arm of Alibaba Group, the natural traffic comes with related brand benefits; Alibaba Health's core pharmaceutical direct sales and e-commerce platform businesses are thus boosted to a great extent. Three specific edges are worth mentioning. First, brand power drives growth. In 2021, Alibaba has grown its brand value by 32% year-on-year to USD 201.86 billion, with a 2nd ranking domestically and 7th ranking globally. As one of the most valuable brands, consumers are more likely to pay a value premium for the products with this recognizable name, or for the creditability it owns. This is indeed what is going on with Alibaba Health. For the 12 months ended March 31, 2021, the revenue from drugs generated from the pharmaceutical direct sales business under the brand of 'Alibaba Health' increased by 86.1% year-on-year, accounting for 64.8% of the revenue of the business. And the number of annual active users of the direct online stores in the reporting period reached a record high of 81 million. Second, synergistic benefits of Alibaba's ecosystem. The synergy effect is most difficult or even impossible to be imitated by competitors. When looking back at Alibaba's business scope, we could see it has already laid out a lot – Alipay's insurance services and 'Future Hospital' plan, O2O medicine delivery service on takeaway platform and hospital-specialized modules on DingTalk – most major businesses owned by Alibaba have medical-related s. With continuous investment in these business-to-consumer marketplace made by the Group, Alibaba Health is able to enhance health awareness and acquire new customers at relatively low acquisition costs, which lays a strong foundation for future growth. As of March 31, 2021, the number of annual active users had exceeded 280 million on Tmall's Pharmaceutical Platform while Alipay's healthcare channel as a whole reached over 520 million annual active users for the fiscal year. Third, empowerment of big data. As a wholly-owned subsidiary of Alibaba with deep roots in the Internet, Alibaba Health's capabilities and resources are naturally geared towards leveraging the prowess of the Internet, big data and Cloud computing. To further boost its digital infrastructure business, for example, tracking platform 'Ma Shang Fang Xin' and digital health business, Alibaba Health has been working closely with Alibaba Cloud to lead the healthcare area. In addition, it also focuses on digital infrastructure. Based on the Group's internal AI, big data, payment and IT capabilities, Alibaba Health is working on exploring the construction of intelligent medical systems, such as AI-assisted diagnostic decision-making, remote imaging platforms and blockchain data security solutions in major hospitals and regions. Future in the mist The future won't be easy for both Alibaba Health and JD Health, as the competition is intensifying. Except for the 'peer pressure,' some inherent problems exist in the essence of most healthcare services – those are mainly related to professionalism, trust and quality. It is partly because of the particularity of healthcare services and pharmaceutical drugs along with the recent market chaos, the government has tightened supervision increasingly, more than ever before. Rory Green, a China economist at TS Lombard, said that the healthcare sector is the only one not hit by regulatory scrutiny yet but is particularly vulnerable, which may possibly make it the next target. For the full article with the charts, please visit the original link.
HKEX:241
by EqualOcean
NUMI 1000% move potential - are you in?This daily chart is a beauty setup. Just listed today December 16th on the TSX (graduated from the TSXV) and far undervalued compared to its peers. Bonus facts: - Health Canada licenses, some exclusive - Strong influencer on regulatory market - Multiple successful clinical trials - NO DEBT - and a warchest full of cash - Some big acquisitions this year, becoming a corporate umbrella with multiple lines of business - Awesome Management team - Well managed financials Need I say more? Get this gem before everyone else finds out about it. Likely to follow MMED.
NEO:NUMILong
by Shadowfigure
$MIRM sniper edition #2*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Recap: My team entered $MIRM on October 29, 2021 at $15.70 per share. Our first take profit is at $21. My team averaged down on our position today at $13.57 per share bringing our share average to $14.63 per share. Our First Entry: $15.70 Our 2nd Entry: $13.57 First Take Profit: $21 2nd Take Profit: $26 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:MIRMLong
by SimplyShowMeTheMoney
long $CMPSLooks like the MACD is still heading down but curling up. RSI is bottoming out as it reaches an important level of support. I think the risk reward at the $28 level is optimal. If you have a high risk tolerance, buy now. Shrooms are already decriminalized in Denver and are about to be in Detroit. The TAM which was initially an imaginative number is now becoming real for Compass Pathways. Go long CMPS www.freep.com Looks ready to find a floor and launch on the weekly chart.
NASDAQ:CMPSLong
by EBITDAtiger
2
our beloved $ATOS *This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* $ATOS remains my teams best trade yet, but sadly for you guys this was before we got serious about documenting our trades here at tradingview. Long story short our guys charted and caught an enormous jump from $1.50 to $9+ per share earlier this year. My team entered $ATOS again today at $2.75 per share and have set our first take profit at $4. ENTRY: $2.75 TAKE PROFIT 1: $4 TAKE PROFIT 2: $6.50 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:ATOSLong
by SimplyShowMeTheMoney